Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000303060 | SCV000338851 | uncertain significance | not provided | 2016-02-02 | criteria provided, single submitter | clinical testing | |
Ce |
RCV000303060 | SCV002564138 | likely pathogenic | not provided | 2022-05-01 | criteria provided, single submitter | clinical testing | EMD: PM1, PM2, PM5, PP4, PS3:Supporting, PS4:Supporting |
Labcorp Genetics |
RCV002519189 | SCV003268697 | uncertain significance | X-linked Emery-Dreifuss muscular dystrophy | 2021-12-24 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. This variant disrupts the p.Pro183 amino acid residue in EMD. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 10393813, 17067998, 26415001, 26675233). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). ClinVar contains an entry for this variant (Variation ID: 285707). This variant has not been reported in the literature in individuals affected with EMD-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces proline, which is neutral and non-polar, with leucine, which is neutral and non-polar, at codon 183 of the EMD protein (p.Pro183Leu). |